PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center

Despite a wealth of preclinical studies, it is unclear whether PIK3CA or PTEN gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abnormalities, PIK3CA mutations were found in 9% (146/1,589), and PTEN loss and/or muta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Janku, Filip, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Falchook, Gerald S., Tsimberidou, Apostolia M., Stepanek, Vanda M., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Zinner, Ralph G., Broaddus, Russell R., Wheler, Jennifer J., Kurzrock, Razelle
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4409143/
https://ncbi.nlm.nih.gov/pubmed/24440717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2013.12.035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados